Opinion

Video

Positioning Biosimilars in Clinical Practice

Author(s):

Ryan Haumschild, PharmD, MS, MBA, CPEL,Casey Butrus, PharmD

Panelists discuss how biosimilars are gaining traction through targeted education, cost-effectiveness analysis, and rigorous clinical validation, with providers increasingly integrating these alternatives by addressing knowledge barriers and demonstrating comparable therapeutic performance.

Video content above is prompted by the following:

  • How are providers positioning biosimilars in their treatment algorithms? What can be done to increase provider confidence in biosimilars?
Related Videos
Frederick L. Locke, MD
2 experts in this video
Dr Rebecca Haberman
1 expert is featured in this series.
Dr Rebecca Haberman
5 experts are featured in this series.
5 experts are featured in this series.
Katie Abouzahr, MD
Related Content
AChR-Ab titers and the AChR-Ab rates of change correlated with myasthenia gravis disease severity scores in a recent study. | Image credit: luchschenF - stock.adobe.com
February 21st 2025

AChR-Ab Titers Associated With Myasthenia Gravis Severity

Rose McNulty
Anti-acetylcholine receptor antibody (AChR-Ab) titers and the AChR-Ab rates of change correlated with myasthenia gravis disease severity scores in a recent study.
managed care cast logo
December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick
On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.
FDA Approved. | Image Credit: Nirusmee - stock.adobe.com
February 20th 2025

First Insulin Aspart Biosimilar Receives FDA Approval

Cameron Santoro
Merilog (insulin-aspart-szjj) is the first rapid-acting insulin biosimilar to Novolog (insulin aspart) that is designated to improve glycemic control in adults and adolescents with type 2 diabetes.
Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi
December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.
COVID-19 pandemic illustration | Image Credit: James Thew - stock.adobe.com
February 20th 2025

Ovarian Cancer Remission Rates Remained Stable Before, After COVID-19 Pandemic

Brooke McCormick
The comparable rates of remission pre- and post-pandemic suggest that COVID-19 did not negatively impact the outcomes of patients with ovarian cancer.
Noelle LoConte, MD | Image credit: University of Wisconsin
February 19th 2025

What Recent Evidence Is Telling Us About Alcohol and Cancer

Produced by Mary Caffrey
Evidence shows alcohol increases estrogen, raising breast cancer risk, with pandemic-related consumption spikes among women.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo